Allergic presentation management for the tACP and EP

 Clinical Guidance for the Management of Allergic Emergencies in the NHS: An Expert Teaching Report for Advanced Clinical Practitioners

The management of allergic disease within the United Kingdom's National Health Service (NHS) Emergency Department (ED) environment requires a sophisticated synthesis of immunological theory, rapid clinical assessment, and adherence to evolving evidence-based guidelines. The Royal College of Emergency Medicine (RCEM) Advanced Clinical Practitioner (ACP) curriculum identifies several core presentations—Acute Allergy (AP1), Drug Allergy (AC1), Anaphylactoid Reactions (AP2), Angioedema (AP3), and Urticaria (AP4)—as essential competencies for clinicians working at an advanced level of practice.[1] These conditions share a spectrum of pathophysiology but diverge significantly in their emergency management, long-term risk profiles, and the specific diagnostic pathways required for safe patient disposition.[2] Given that hypersensitivity reactions are a frequent reason for ED attendance, often involving time-critical interventions where delays can lead to fatal outcomes, a deep understanding of the underlying mechanisms and the most recent Resuscitation Council UK (RCUK) and National Institute for Health and Care Excellence (NICE) guidance is paramount for the practitioner.[2, 3]

Pathophysiology and Immunological Mechanisms of Hypersensitivity

The immunological basis of allergy is rooted in the body’s hypersensitivity to exogenous substances that are typically harmless to the majority of the population. Traditionally, the Gell and Coombs classification system categorizes these into four types, with Type I (immediate) and Type IV (delayed) being the most relevant to the emergency presentations encountered by ACPs.[4, 5] Understanding the cellular and molecular events that lead to the clinical manifestations of allergy allows the practitioner to anticipate the progression of symptoms and select targeted interventions.

Type I Hypersensitivity: The IgE-Mediated Cascade

Immediate hypersensitivity reactions are primarily driven by Immunoglobulin E (IgE), a specialized class of antibody. This process begins with a sensitization phase, where an individual is exposed to an allergen, leading to the production of antigen-specific IgE by B-lymphocytes and plasma cells.[5] These IgE molecules do not remain free in the serum for long; they bind to high-affinity $FcϵRI$ receptors located on the surface of mast cells, which are prevalent in skin and mucosal tissues, and basophils, which circulate in the blood.[5] This state of sensitization is asymptomatic and can persist for years.

Upon subsequent re-exposure to the same allergen, the substance binds to and cross-links the IgE molecules already present on the mast cell surface. This cross-linking serves as a mechanical and biochemical signal that triggers the immediate degranulation of the cell.[5, 6] The resulting release of preformed mediators occurs within seconds to minutes. Histamine is the most prominent mediator, acting on $H_1$ and $H_2$ receptors to induce localized or systemic vasodilation and increased capillary permeability.[2] These vascular changes allow fluid to leak into the interstitial spaces, manifesting clinically as the dermal edema of urticaria or the deeper tissue swelling characteristic of angioedema.[2, 5] In systemic reactions, these mediators cause widespread vasodilation, which may lead to distributive shock, and bronchial smooth muscle contraction, resulting in wheezing and airway compromise.[6]

Non-IgE Mediated and Anaphylactoid Mechanisms

The curriculum includes "anaphylactoid" reactions (AP2), a term that has historically been used to describe systemic reactions that mimic anaphylaxis in their clinical presentation but occur without the requirement for prior sensitization or IgE involvement.[7] In modern clinical nomenclature, such as that proposed by the World Allergy Organization (WAO), these are often grouped under the broader umbrella of "non-immunologic anaphylaxis".[7, 8]

These reactions result from the direct, non-specific activation of mast cells and basophils. Common triggers include certain medications, such as intravenous radiocontrast media, opiates, and vancomycin (often associated with 'red man syndrome'), as well as physical triggers like extreme cold, heat, or strenuous exercise.[5, 6, 9] Furthermore, the activation of the complement cascade—specifically the production of anaphylatoxins such as C3a, C4a, and C5a—can lead to direct mast cell degranulation by binding to non-Fc$ϵ$RI receptors on the cell membrane.[5, 9] While the triggering mechanism is fundamentally different from IgE-mediated allergy, the final common pathway involves the release of identical inflammatory mediators. Consequently, the clinical management of the resulting systemic response remains identical to that of classic anaphylaxis, and the practitioner should not delay the administration of adrenaline based on the suspected mechanism.[7, 8]

Comparison of Mechanisms	IgE-Mediated (Anaphylaxis)	Non-IgE Mediated (Anaphylactoid)
Prior Sensitization	Required	Not required
Antibody Involved	IgE	None
Cellular Target	Mast cells and basophils	Mast cells and basophils
Onset of Symptoms	Rapid (minutes)	Rapid (minutes)
Typical Triggers	Peanuts, bee stings, penicillin	Radiocontrast, opiates, cold, exercise
First-line Treatment	IM Adrenaline	IM Adrenaline

Acute Allergy and Anaphylaxis: Clinical Recognition and Emergency Treatment

Anaphylaxis is the most severe manifestation of acute allergy (AP1), characterized by a life-threatening, generalized or systemic hypersensitivity reaction.[6, 10] In the UK, the Resuscitation Council (RCUK) published updated guidelines in 2021, which introduced significant changes to the recognition, pharmacological management, and post-stabilization observation of these patients.[10, 11, 12]

Diagnostic Criteria and Clinical Assessment

Anaphylaxis is primarily a clinical diagnosis, and the practitioner must be prepared to act before the full syndrome has necessarily unfolded. The RCUK guidelines suggest that anaphylaxis is highly likely when three specific criteria are met: an acute onset and rapid progression of symptoms, life-threatening Airway (A) and/or Breathing (B) and/or Circulation (C) problems, and usually, skin and/or mucosal changes such as flushing, urticaria, or angioedema.[6, 8, 11]

It is a common clinical misconception that skin changes must be present for a diagnosis of anaphylaxis. Evidence indicates that cutaneous features may be subtle or entirely absent in up to 10-20% of reactions, particularly those presenting with rapid-onset hypotension or in cases of severe food-triggered anaphylaxis.[3, 6, 11] Therefore, the ACP must maintain a high index of suspicion in any patient who presents with sudden cardiovascular collapse or acute respiratory distress following exposure to a known or suspected trigger.[3, 8]

The life-threatening features of anaphylaxis can be categorized as follows:

• Airway: Pharyngeal or laryngeal edema, manifesting as a hoarse voice, stridor, or a feeling of throat tightness.[6, 7]
• Breathing: Bronchospasm, wheezing, tachypnea, and increased work of breathing, which can rapidly progress to respiratory exhaustion and cyanosis.[6, 7]
• Circulation: Hypotension, tachycardia, and signs of shock such as cool, clammy skin or confusion.[6, 8] Cardiovascular collapse can be exacerbated by sudden changes in posture; moving a patient from a supine to a standing position can lead to a fatal reduction in venous return and myocardial filling.[8, 11]

The Role of Adrenaline as First-Line Therapy

Adrenaline remains the cornerstone of anaphylaxis treatment. It acts rapidly as a physiological antagonist to the effects of histamine and other mediators. Through its $\alpha$-adrenergic effects, it induces peripheral vasoconstriction, thereby increasing systemic vascular resistance and reducing mucosal edema.[2, 6] Its $\beta$-adrenergic effects provide bronchodilation and increase myocardial contractility, while also stabilizing mast cell membranes to prevent further mediator release.[6]

The 2021 guidelines emphasize that adrenaline should be administered via the intramuscular (IM) route into the anterolateral thigh as soon as the diagnosis is suspected.[3, 11, 12] The IM route is preferred over the subcutaneous or deltoid routes because it achieves peak plasma concentrations significantly faster—up to seven times faster than an injection in the arm.[3] Furthermore, a single IM dose is well-tolerated with minimal risk of serious side effects in the context of a life-threatening reaction.[11]

Patient Group	Adrenaline Dose (IM 1:1000)
Adult	500 micrograms (0.5 mL)
Child > 12 years	500 micrograms (0.5 mL)
Child 6 - 12 years	300 micrograms (0.3 mL)
Child 6 months - 6 years	150 micrograms (0.15 mL)
Infant < 6 months	25 micrograms (0.025 mL)

If the initial dose does not lead to clinical improvement, the practitioner should not hesitate to repeat the IM dose every 5 minutes while preparing for more advanced interventions.[8, 11, 12]

Management of Refractory Anaphylaxis and Adjunctive Therapies

Refractory anaphylaxis is defined as a reaction where life-threatening airway, breathing, or circulation problems persist despite two appropriate doses of IM adrenaline.[11, 12] In such critical scenarios, the ACP must escalate care immediately, calling for senior anesthetic or critical care support to initiate an intravenous (IV) adrenaline infusion.[11, 12] IV adrenaline boluses are dangerous and should be avoided outside of the perioperative or cardiac arrest setting, as they are associated with severe hypertension, myocardial ischemia, and arrhythmias.[6, 11, 12]

Concurrently, aggressive fluid resuscitation is required. Anaphylaxis causes a massive shift of fluid from the intravascular to the extravascular space due to increased capillary permeability. For patients with circulatory compromise, a crystalloid bolus (e.g., 20 mL/kg in children or 500-1000 mL in adults) should be administered and repeated as necessary.[8, 11, 12]

A significant shift in the 2021 RCUK guidelines is the removal of corticosteroids (e.g., hydrocortisone) and antihistamines (e.g., chlorphenamine) from the routine first-line emergency management of anaphylaxis.[11, 12, 13] Evidence has shown that these medications do not treat the life-threatening features of a reaction and do not reliably prevent the occurrence of biphasic reactions.[12, 14] Antihistamines may be used as a third-line intervention only after the patient is stable, primarily to manage cutaneous symptoms like itching or urticaria.[11, 12, 13]

Urticaria (AP4): Recognition, Triggers, and Management

Urticaria, frequently referred to as hives, wheals, or nettle rash, is one of the most common dermatological presentations in the Emergency Department, affecting approximately one in five individuals at some point during their lifetime.[9, 15] While it is often a benign and self-limiting condition, it can cause significant distress and may be an early sign of a more severe systemic reaction.[15, 16]

Clinical Presentation and Differentiation

The characteristic lesion of urticaria is the wheal—a raised, erythematous, and intensely pruritic area of skin edema.[2, 16] A defining feature of acute urticaria is the transient nature of individual lesions; they typically resolve within 24 hours, often disappearing in one area and reappearing in another, without leaving any permanent skin changes or bruising.[9, 15]

The practitioner should be aware of several clinical variants and "red flags" that may suggest a different diagnosis. If the lesions are painful or burning rather than itchy, last for more than 48 hours, or leave residual purpura or hyperpigmentation upon resolution, the diagnosis of urticarial vasculitis should be considered, which requires further investigation for systemic autoimmune disease.[9, 16] Furthermore, urticaria that persists for more than six weeks is classified as chronic urticaria, which often has an idiopathic or autoimmune basis and requires outpatient specialist review rather than emergency intervention.[15, 16]

Identifying Triggers in the ED Population

Identifying the trigger for acute urticaria is a key part of the emergency assessment, although in many cases, a definitive cause is never found. In the pediatric population, the vast majority of acute urticaria episodes are associated with viral infections.[15, 16] In adults, common triggers include:

• Medications: Antibiotics (especially penicillins) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are the most frequent pharmaceutical causes.[9]
• Foods: Immediate reactions to nuts, eggs, milk, fish, and shellfish are common.[9, 12]
• Physical Factors: Exposure to cold (cold urticaria), heat, sunlight (solar urticaria), or pressure can trigger mast cell degranulation in susceptible individuals.[2, 16]
• Insect Venom: Bee and wasp stings can cause localized or generalized urticaria.[6]

Urticaria vs. Mimics	Acute Urticaria	Erythema Multiforme	Urticarial Vasculitis
Primary Sensation	Itching	Mild itching/Burning	Pain/Burning
Lesion Duration	< 24 hours	Days	> 24-48 hours
Target Lesions	Absent	Characteristic	Absent
Residual Marks	None	Possible pigmentation	Purpura/Bruising

Pharmacotherapy and Patient Disposition

The primary treatment for acute urticaria is the use of $H_1$-receptor antagonists. Modern, second-generation, non-sedating antihistamines such as cetirizine, fexofenadine, or loratadine are strongly preferred over older agents like chlorphenamine.[11, 15, 16] These newer agents are more effective, have a longer duration of action, and do not cross the blood-brain barrier significantly, thereby avoiding the sedation and cognitive impairment associated with first-generation drugs.[15, 16]

In severe cases of acute urticaria where there is significant discomfort, a short course (3-5 days) of oral corticosteroids may be considered to accelerate symptom resolution, although their routine use is not supported by strong evidence.[3, 15] Most patients with isolated urticaria do not require admission and can be discharged with advice to avoid known triggers and continue oral antihistamines as needed.[2, 15]

Angioedema (AP3): Differentiating Allergic and Bradykinin-Mediated Forms

Angioedema represents a deeper, more severe form of tissue swelling involving the subcutaneous and submucosal layers.[2, 17] Because it can involve the upper airway, it is a high-risk presentation that requires immediate assessment for potential obstruction.[2, 17, 18] A fundamental skill for the ACP is the ability to differentiate between histamine-mediated (allergic) and bradykinin-mediated (non-allergic) angioedema, as the two types require radically different therapeutic approaches.[18, 19, 20]

Histamine-Mediated (Allergic) Angioedema

The majority of angioedema cases seen in the ED—approximately 90%—are histamine-mediated.[2] These reactions often occur in conjunction with urticaria and are characterized by rapid onset and intense pruritus.[2, 9, 19] The management follows the same principles as the treatment of anaphylaxis or acute allergy, utilizing adrenaline, antihistamines, and corticosteroids as needed.[2, 19]

Bradykinin-Mediated Angioedema

Bradykinin-mediated angioedema is a non-allergic process characterized by the absence of urticaria and itching.[2, 17, 19] It tends to have a more gradual onset and a longer duration (often lasting 2 to 5 days) compared to allergic forms.[17, 19] Crucially, bradykinin-mediated angioedema does not respond to adrenaline, antihistamines, or steroids, as the underlying inflammatory driver is not mast cell degranulation but the excessive accumulation of the vasoactive peptide bradykinin.[18, 19, 20]

ACE Inhibitor-Induced Angioedema

Angiotensin-converting enzyme (ACE) inhibitors are the most common cause of non-allergic angioedema encountered in the ED.[18, 19] ACE is one of the primary enzymes responsible for the degradation of bradykinin; its inhibition leads to elevated levels of the peptide, which induces vasodilation and increased vascular permeability.[18, 19] This reaction can occur at any time during therapy, even after several years of uneventful use.[2, 19] The lips, tongue, and face are the most common sites of involvement.[17, 18, 19]

Hereditary Angioedema (HAE)

HAE is a rare but life-threatening autosomal dominant disorder caused by a deficiency (Type I) or functional impairment (Type II) of the C1 esterase inhibitor (C1-INH).[2, 18] C1-INH is a key regulator of the contact system; its absence allows for the uncontrolled production of bradykinin.[17, 19] HAE typically presents with recurrent episodes of non-pruritic swelling of the extremities, face, airway, or gastrointestinal tract.[17, 19] Gastrointestinal involvement is common, presenting as severe, crampy abdominal pain and vomiting due to bowel wall edema—symptoms that are frequently misdiagnosed as an acute surgical abdomen.[2, 17]

Feature	Histamine-Mediated	Bradykinin-Mediated
Urticaria/Itching	Present	Absent
Onset of Swelling	Minutes to Hours	Hours to Days
Gastrointestinal Pain	Rare	Common in HAE
Response to Standard Allergy Meds	Good	Poor
Likely Etiology	Foods, insects, drugs	ACE inhibitors, HAE

Specialized Management of Bradykinin-Mediated Reactions

When a practitioner suspects bradykinin-mediated angioedema, they must look beyond the standard anaphylaxis kit. The management of these patients involves:

• Airway Protection: Close monitoring is essential, as the swelling may progress over several hours. Stridor, voice change, or difficulty swallowing should prompt immediate anesthetic consultation and consideration of fiberoptic nasopharyngolaryngoscopy (NPL).[9, 18]
• Icatibant: This is a synthetic bradykinin $B_2$ receptor antagonist. It is administered as a subcutaneous injection and can provide rapid symptom relief in both HAE and severe ACE inhibitor-induced reactions.[2, 18]
• C1-INH Concentrate: (e.g., Berinert or Cinryze) replaces the missing protein in patients with HAE.[2, 19]
• Fresh Frozen Plasma (FFP): In emergencies where specific concentrates or antagonists are unavailable, two units of FFP can be used, as FFP contains native C1 esterase inhibitor.[2]

All patients with suspected non-allergic angioedema must have their offending medications (like ACE inhibitors) discontinued immediately and should be referred to a specialist immunology service for further diagnostic testing, including C4 levels and functional C1-INH assays.[2, 19]

Drug Allergy (AC1): Diagnosis, Documentation, and NICE Guidance

Drug allergy is a specific and high-stakes subset of acute allergy (AP1) that requires meticulous diagnosis and documentation to prevent future adverse events.[21, 22] The National Institute for Health and Care Excellence (NICE) guideline CG183 provides a comprehensive framework for the assessment and referral of these patients within the NHS.[21, 23]

Systematic Assessment and Documentation

The practitioner must distinguish between a true drug allergy (hypersensitivity) and a non-allergic adverse drug reaction (side effect). A true drug allergy is defined as any reaction due to a drug that has clinical features compatible with hypersensitivity, regardless of the underlying mechanism.[24]

To improve patient safety and avoid the risks associated with inaccurate allergy labeling, NICE recommends a structured approach to documentation. When a person presents with a suspected drug allergy, the clinical records should include:

• The generic and proprietary name of the suspected drug(s).[25]
• A detailed description of the reaction (signs and symptoms).[25]
• The indication for which the drug was being taken.[25]
• The timing of the reaction relative to the dose (number of doses taken or days on the drug).[25]
• The route of administration.[25]

NICE CG183 Structured Assessment Boxes

NICE uses a three-box system to categorize suspected drug allergies based on the clinical presentation and timing of onset.[25, 26]

Category	Typical Signs	Timing of Onset
Box 1: Immediate Reactions	Anaphylaxis, urticaria, angioedema, asthma exacerbation.	Usually < 1 hour after exposure.
Box 2: Non-immediate (No systemic)	Widespread red macules or papules (exanthema-like), fixed drug eruption.	Usually 6-10 days after 1st dose, or < 3 days after 2nd dose.
Box 3: Non-immediate (With systemic)	DRESS, SJS, TEN, organ dysfunction (hepatitis, nephritis).	Variable: DRESS (2-6 weeks), SJS/TEN (7-14 days).

The "Penicillin Allergy" Label and Its Implications

A significant challenge for ACPs is the high prevalence of reported penicillin (beta-lactam) allergies. Research suggests that up to 90% of patients who believe they are allergic to penicillin are found to be tolerant upon formal specialist testing.[4, 25] These inaccurate labels are not harmless; they lead to the use of broader-spectrum antibiotics (such as quinolones or vancomycin), which are associated with increased rates of Clostridioides difficile infection, multi-drug resistant organisms, and longer hospital stays.[4, 21]

NICE recommends that patients with suspected beta-lactam allergy should be referred to a specialist drug allergy service if they have conditions that can only be treated with beta-lactams or if they are likely to require frequent antibiotic therapy in the future.[4, 25]

Severe Cutaneous Adverse Reactions (SCARS)

ACPs must maintain a high level of vigilance for Box 3 reactions, particularly Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).[4, 26] These are life-threatening conditions characterized by a prodrome of fever and malaise, followed by the development of painful skin blistering, mucosal ulceration (eyes, mouth, genitalia), and epidermal detachment.[4, 26] Unlike simple urticaria, these reactions involve T-cell mediated destruction of keratinocytes. Any patient with suspected SJS/TEN requires immediate cessation of all non-essential medications and urgent admission to a specialist burn or dermatology unit.[4]

Diagnostic Investigations: The Role of Mast Cell Tryptase

In the acute setting, laboratory tests have limited utility in the immediate management of allergy, with one critical exception: mast cell tryptase.[2, 27] Tryptase is a protease stored in the secretory granules of mast cells. Its elevation in the blood is a highly specific marker of mast cell degranulation, making it an invaluable tool for confirming a diagnosis of anaphylaxis when the clinical presentation is uncertain.[2, 27]

The Three-Sample Protocol

Because tryptase levels peak and decline rapidly, a single measurement is often insufficient to distinguish between a significant acute reaction and a high baseline level (which can occur in conditions like systemic mastocytosis).[6, 27] The RCUK and NICE recommend a specific timing for samples [6, 10]:

1. Sample 1: As soon as feasible after emergency treatment has started (this sample provides a comparison point but may be normal if taken too early).[6, 10]
2. Sample 2: Ideally within 1 to 2 hours of the onset of symptoms (but no later than 4 hours). This sample captures the peak tryptase level.[2, 6, 10]
3. Sample 3: At least 24 hours after the complete resolution of symptoms (or in convalescence). This sample establishes the patient's true baseline level.[6, 10]

The time of each sample relative to the onset of symptoms must be clearly documented. It is important to note that while a raised tryptase supports a diagnosis of anaphylaxis, a normal level does not exclude it, particularly in cases of food-triggered reactions or those presenting solely with hypotension.[8, 10]

Discharge, Follow-up, and Patient Safety Netting

The responsibility of the ED clinician does not end when the acute symptoms of a reaction have resolved. Ensuring long-term patient safety through education, the provision of emergency medication, and appropriate specialist referral is a mandatory requirement.[10, 11, 28]

Observation Periods Following Anaphylaxis

The optimal duration of observation following the successful treatment of anaphylaxis remains a subject of debate, as the risk of a biphasic reaction—where symptoms recur without further exposure to the allergen—must be balanced against resource utilization.[28, 29, 30] Biphasic reactions occur in approximately 5% of cases, with a median onset of around 12 hours.[10, 29]

Based on the 2021 RCUK guidelines, the recommended observation times are:

• Minimum 2 hours: Only for patients with a very mild reaction that responded rapidly to a single dose of adrenaline, provided they have no risk factors for severe disease.[8, 11]
• Minimum 6 hours: The standard recommendation for most patients who presented with respiratory or circulatory symptoms.[8, 10, 11]
• Minimum 12 hours (or overnight): Required for patients who needed more than two doses of adrenaline, had a severe initial presentation, or have a history of poorly controlled asthma.[8, 11]

Before discharge, the ACP must ensure the patient can stand without dizziness (to check for postural hypotension) and has safely consumed food to ensure no late absorption of a gut allergen will trigger a recurrence.[10]

The Provision of Adrenaline Auto-Injectors (AAIs)

All patients who have experienced a suspected anaphylactic reaction (unless it was purely drug-induced and the drug can be easily avoided) must be prescribed two adrenaline auto-injectors (e.g., EpiPen, Jext, or Emerade) upon discharge.[10, 11, 28, 31] The provision of two devices is essential because a second dose may be required if the first is ineffective or if symptoms recur before medical help arrives.[3, 32]

Crucially, the practitioner must ensure that the patient (or their carer) receives practical training on how to use the specific brand of device prescribed, as the mechanics of administration vary between manufacturers.[28, 31, 32, 33]

Specialist Referral and Action Plans

Referral to a specialist allergy clinic is mandatory for all patients who have experienced anaphylaxis.[10, 11, 34] The specialist clinic will perform formal investigations (such as skin prick testing or specific IgE blood tests) to confirm the trigger and provide long-term management strategies.[4, 21, 31]

In the interim period between the ED visit and the specialist appointment, patients should be provided with a written Allergy Action Plan, such as those provided by the British Society for Allergy and Clinical Immunology (BSACI).[31, 33] These plans use simple language to help patients recognize early "red flag" symptoms and provide clear instructions on when and how to use their emergency medications.[31, 35]

MHRA Yellow Card Reporting

The reporting of suspected Adverse Drug Reactions (ADRs) to the Medicines and Healthcare products Regulatory Agency (MHRA) via the Yellow Card Scheme is a critical part of post-marketing drug surveillance in the UK.[23, 36, 37] Clinicians are encouraged to report any reaction they suspect is drug-related, even if causality has not been definitively proven.[37, 38] Reporting is mandatory for:

• Serious Reactions: Any reaction that is life-threatening, fatal, results in hospitalization, or is medically significant (e.g., anaphylaxis, SJS/TEN).[37, 39]
• Black Triangle Drugs (▼): New medications that are under intensive monitoring.[37, 38]
• Pediatric Cases: All suspected ADRs in children, including those involving off-label use.[39]

Reports can be submitted via the Yellow Card website, the dedicated mobile app, or directly through hospital electronic prescribing systems.[37, 40]

Educational Framework: Integrating Allergy into ACP Training

The management of allergic emergencies is not only a clinical requirement but also a cornerstone of the professional development of Advanced Clinical Practitioners in Emergency Medicine.[41, 42] The RCEM 2022 curriculum structures these competencies through Specialty Learning Outcomes (SLOs), which are framed as high-level activities that an ACP must be able to perform.[43, 44]

Mapping to Specialty Learning Outcomes (SLOs)

The presentations discussed—AP1 through AP4—map to several critical SLOs:

• SLO1 & SLO3: Managing physiologically stable patients and identifying/resuscitating the acutely sick patient. Anaphylaxis management is the quintessential test of an ACP's ability to transition rapidly between these two states.[43]
• SLO2: Making safe clinical decisions and answering clinical questions. Differentiating between histamine and bradykinin angioedema is a prime example of complex clinical decision-making required at the advanced level.[41, 43]
• SLO6: Delivering key procedural skills, such as the safe and timely administration of intramuscular and intravenous medications.[43]

Evidencing Competence for Credentialing

To achieve credentialing, the trainee ACP (tACP) must provide robust evidence of their competence in managing allergic emergencies in their ePortfolio (risr/advance).[44, 45] This evidence should include:

• Workplace-Based Assessments (WPBAs): Mini-Clinical Evaluation Exercises (Mini-CEX) and Case-Based Discussions (CBDs) that focus on real-life allergy presentations, emphasizing the practitioner's rationale for treatment and their adherence to national guidelines.[44, 45]
• Simulation: Participation in high-fidelity simulation sessions focusing on refractory anaphylaxis or the management of life-threatening airway angioedema.[44, 46]
• Reflective Practice: Detailed reflections on cases, particularly those involving "human factors," such as decision bias or the challenges of managing high-risk elderly patients with multiple comorbidities.[41, 46]

By achieving an Entrustment Level 2b for these conditions—meaning they can manage the presentation independently with a supervisor available on the shop floor—the ACP demonstrates that they are a safe, competent, and high-functioning member of the emergency medical team.[41, 43, 46]

Conclusion: Synthesis of Clinical Priorities

The effective management of allergic emergencies in the NHS Emergency Department requires a disciplined adherence to contemporary evidence-based guidelines and a deep understanding of the physiological mechanisms at play. From the rapid recognition and treatment of anaphylaxis with IM adrenaline according to the 2021 RCUK guidelines, to the meticulous documentation of drug allergies as mandated by NICE CG183, the Advanced Clinical Practitioner plays a pivotal role in ensuring patient safety.[10, 11, 21] The ability to differentiate between histamine-mediated and bradykinin-mediated angioedema ensures that patients receive life-saving treatments like Icatibant or C1-INH concentrates rather than ineffective conventional allergy medications.[2, 19] Finally, the commitment to comprehensive safety netting—through the provision of dual auto-injectors, written action plans, and timely specialist referrals—provides the ultimate defense against the unpredictable and potentially fatal nature of recurrent hypersensitivity reactions.[10, 11, 28, 31] Through continuous professional development and the rigorous application of these clinical standards, ACPs contribute significantly to the delivery of high-quality emergency care within the NHS.

--------------------------------------------------------------------------------

1. The Syllabus - RCEMCurriculum, https://rcemcurriculum.co.uk/the-syllabus/
2. Angioedema - RCEMLearning, https://www.rcemlearning.co.uk/reference/angioedema/
3. Episode 78 –Anaphylaxis & Anaphylactic Shock Live from EM Cases Course, https://emergencymedicinecases.com/wp-content/uploads/filebase/pdf/Episode-078-Mar2016-Anaphylaxis.pdf
4. Signs of Medication Allergy: Symptoms, Diagnosis and NHS Management, https://www.boltpharmacy.co.uk/guide/signs-of-medication-allergy
5. Pathophysiology of bradykinin and histamine mediated angioedema - Frontiers, https://www.frontiersin.org/journals/allergy/articles/10.3389/falgy.2023.1263432/full
6. Anaphylaxis - RCEMLearning, https://www.rcemlearning.co.uk/reference/anaphylaxis/
7. Assessment and referral after emergency treatment of a suspected anaphylactic episode: Summary of NICE guidance | Request PDF - ResearchGate, https://www.researchgate.net/publication/51881452_Assessment_and_referral_after_emergency_treatment_of_a_suspected_anaphylactic_episode_Summary_of_NICE_guidance
8. Emergency treatment of anaphylaxis: concise clinical guidance - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC9345203/
9. Clinical Practice Guideline: Initial Evaluation and Management of Patients Presenting with Acute Urticaria or Angioedema - AAEM, https://www.aaem.org/statements/clinical-practice-guideline-initial-evaluation-and-management-of-patients-presenting-with-acute-urticaria-or-angioedema/
10. Emergency treatment of anaphylaxis Guidelines for healthcare ..., https://www.resus.org.uk/sites/default/files/2021-05/Emergency%20Treatment%20of%20Anaphylaxis%20May%202021_0.pdf
11. Anaphylaxis Summary Document.pdf - Resuscitation Council, https://www.resus.org.uk/sites/default/files/2021-04/Anaphylaxis%20Summary%20Document.pdf
12. Evidence update for the treatment of anaphylaxis - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC8139870/
13. Recognition and Management of Anaphylaxis - Right Decisions, https://rightdecisions.scot.nhs.uk/media/icni4wab/anaphylaxis-recognition-and-management-v4-482.pdf
14. Emergency management of anaphylaxis and the impact of the new UK advanced life support guidelines - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12581685/
15. Urticaria and Angioedema - University Hospitals Sussex NHS Foundation Trust, https://www.uhsussex.nhs.uk/resources/urticaria-and-angioedema/
16. Urticaria and Angioedema - Information for Parents and Carers | Hull University Teaching Hospitals NHS Trust, https://www.hey.nhs.uk/patient-leaflet/urticaria-and-angioedema/
17. Full article: Management of angioedema without urticaria in the emergency department, https://www.tandfonline.com/doi/full/10.3109/07853890.2014.949300
18. Angioedema in the emergency department: a practical guide to differential diagnosis and management - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC5389952/
19. Evaluation and Management of Angioedema in the Emergency Department - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC6625683/
20. Angioedema in the emergency department: a practical guide to differential diagnosis and management - PubMed, https://pubmed.ncbi.nlm.nih.gov/28405953/
21. Managing Drug Allergy: NICE Guideline (CG183) | Anaphylaxis UK, https://www.anaphylaxis.org.uk/healthcare-professionals/nice-quality-standards/managing-drug-allergy-nice-guideline/
22. Recommendations for research | Drug allergy: diagnosis and management | Guidance, https://www.nice.org.uk/guidance/cg183/chapter/Recommendations-for-research
23. Drug allergy: diagnosis and management | Guidance - NICE, https://www.nice.org.uk/guidance/cg183
24. Drug Allergy - BSACI, https://www.bsaci.org/resources/allergy-management/drug-allergy/
25. Guideline summary - Drug Allergy - NCBI Bookshelf - NIH, https://www.ncbi.nlm.nih.gov/books/NBK274153/
26. Quality statement 1: Documentation using the structured assessment ..., https://www.nice.org.uk/guidance/qs97/chapter/quality-statement-1-documentation-using-the-structured-assessment-guide
27. Assessment and referral after emergency treatment of a suspected anaphylactic episode: Summary of the NICE guideline - ResearchGate, https://www.researchgate.net/publication/221979262_Assessment_and_referral_after_emergency_treatment_of_a_suspected_anaphylactic_episode_Summary_of_the_NICE_guideline
28. Anaphylaxis: assessment and referral after emergency treatment | Guidance - NICE, https://www.nice.org.uk/guidance/cg134/ifp/chapter/after-emergency-treatment
29. Evaluating Practice Patterns of Observation Periods Status Post Epinephrine Administration for Anaphylaxis - PubMed, https://pubmed.ncbi.nlm.nih.gov/40857992/
30. Anaphylaxis: assessment and referral after emergency treatment - NICE, https://www.nice.org.uk/researchrecommendation/length-of-observation-period-following-emergency-treatment-for-anaphylaxis-for-how-long-should-a-person-who-has-received-emergency-treatment-for-anaphylaxis-be-observed
31. Adrenaline auto- injector prescription for patients at risk of ... - BSACI, https://www.bsaci.org/wp-content/uploads/2023/06/BSACI-AAI-Guidance-June-2023.pdf
32. Guidance: Anaphylaxis | Resuscitation Council UK, https://www.resus.org.uk/library/additional-guidance/guidance-anaphylaxis
33. Immunology & Allergy Guidelines - Remedy BNSSG ICB, https://remedy.bnssg.icb.nhs.uk/adults/immunology/immunology-allergy-guidelines/
34. Anaphylaxis: assessment and referral after emergency treatment | Guidance - NICE, https://www.nice.org.uk/guidance/cg134
35. Babies, children and young people's experience of healthcare - NICE, https://www.nice.org.uk/guidance/ng204/documents/consultation-comments-and-responses
36. Suspected side effect from a medicine - how to report - RCPCH, https://www.rcpch.ac.uk/resources/suspected-side-effect-medicine-how-report
37. Reporting — Yellow Card Centre North West, https://www.yccnorthwest.nhs.uk/reporting
38. Yellow Card reporting for healthcare professionals - All Wales Therapeutics and Toxicology Centre, https://awttc.nhs.wales/medicines-optimisation-and-safety/yellow-card-centre-wales/reporting-side-effects-of-medicines-and-vaccines/yellow-card-reporting-for-healthcare-professionals/
39. It's easy to report online at www.mhra.gov.uk/yellowcard, https://assets.publishing.service.gov.uk/media/5a81ac1840f0b6230269890f/Healthcare-Professional-Yellow-Card-Reporting-Form_1_.pdf
40. Creating a Yellow Card Report via the Drug Allergy and Intolerance Screen - Vision Help, https://help.visionhealth.co.uk/Vision_Consultation_Manager_Help_Centre/Content/ConMgr/62175.htm
41. The Clinical Syllabus: Coverage, Evidence and Linking to SLOs - RCEM, https://rcem.ac.uk/wp-content/uploads/2025/07/ACP-The-Clinical-syllabus_v2_January-2025.pdf
42. ACP Curriculum Adult Second Edition April 2025 | PDF - Scribd, https://www.scribd.com/document/943425330/ACP-Curriculum-Adult-Second-Edition-April-2025
43. Overview of the Curriculum | RCEM, https://rcem.ac.uk/wp-content/uploads/2025/07/ACP-Curriculum_overview_v1_April-2023.pdf
44. RCEM Emergency Medicine ACP Credentialing, https://rcem.ac.uk/acp-curriculum-2022/
45. RCEM Curriculum - East of England, https://heeoe.hee.nhs.uk/sites/default/files/rcem_generic_specialty_learning_outcomes_v.5.pdf
46. RCEM Emergency Medicine ACP Curriculum (2022) and Credentialing Regulations – second edition release statement, https://rcem.ac.uk/wp-content/uploads/2025/04/ACP-curriculum-and-regulations_second-edition-release-statement.pdf
47. 
    
    
    
48. 

    
    
    
49. 

    
    
    
50. 

    
    
    
51. 
    
52. 

    
    
    
53. 

    
    
    
54. 

    
    
    
55. 

    
    
    
56. 

    
    
    
57. 

    
    
    
58. 

    
    
    
59. 

    
    
    
60. 

    
    
    
61. 

    
    
    
62. 

    
    
    
63. --------------------------------------------------------------------------------

    MEM-EM PODCAST

    
    

                                                                             Apple podcast

    

    
    
    

    
    

    Spotify Podcast

    

    
    

    Amazon Music 
    
    

    

    
    
    

      You Tube Music Podcasts

      

    

    
    

    
    

    Completion certificate